Astellas, Evec team up for fully-human antibody
Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases. Astellas will pay a sum of
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.